Phio Pharmaceuticals Corp (PHIO)

[coinguy]

The 30 day wait period is over

On Aug 12
GEERT CAUWENBERGH: filed our ophthalmology R&D with RXI-109 for retinal scaring a few weeks ago.
PAMELA PAVCO: Thank you, Caitlin. Hello, everyone. For the next few minutes, I will give you an overview of our research and development programs at RXi. I will start with an update on RXI-109 for both our dermal and ophthalmology programs, and then we’ll view our ongoing work with Samcyprone.
First and foremost, at the end of July, we filed an IND for the use of RXI-109 for the treatment of the retinal scarring component of wet age-related macular degeneration or wet AMD. We are currently in the 30-day wait period with the FDA before we can initiate this trial.